Related references
Note: Only part of the references are listed.Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer
M. Chatterjee et al.
ANNALS OF ONCOLOGY (2016)
Cancer Statistics, 2016
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Overspending driven by oversized single dose vials of cancer drugs
Peter B. Bach et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Overspending driven by oversized single dose vials of cancer drugs
Peter B. Bach et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
Amita Patnaik et al.
CLINICAL CANCER RESEARCH (2015)
Receipt of Chemotherapy Among Medicare Patients With Cancer by Type of Supplemental Insurance
Joan L. Warren et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Gregory A. Masters et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Necitumumab in Metastatic Squamous Cell Lung Cancer Establishing a Value-Based Cost
Daniel A. Goldstein et al.
JAMA ONCOLOGY (2015)
Indication-Specific Pricing for Cancer Drugs
Peter B. Bach
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Budget Impact Analysis Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force
Sean D. Sullivan et al.
VALUE IN HEALTH (2014)
ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer
Justin F. Gainor et al.
CLINICAL CANCER RESEARCH (2013)
Referral and Treatment Patterns Among Patients With Stages III and IV Non-Small-Cell Lung Cancer
Bernardo H. L. Goulart et al.
JOURNAL OF ONCOLOGY PRACTICE (2013)
Approval Summary: Pemetrexed in the Initial Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer
Martin H. Cohen et al.
ONCOLOGIST (2009)
Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database
Ramaswamy Govindan et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Share Paper
